Targeting intratumoral hypoxia to enhance anti-tumor immunity

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancers express a large battery of genes by which they establish an immunosuppressive tumor microenvironment. Many of these genes are induced by intratumoral hypoxia through transcriptional activation mediated by hypoxia-inducible factors HIF-1 and HIF-2. This review summarizes several recent reports describing hypoxia-induced mechanisms of immune evasion in sarcoma and breast, colorectal, hepatocellular, prostate and uterine cancer. These studies point to several novel therapeutic approaches to improve anti-tumor immunity and increase responses to immunotherapy.

Original languageEnglish (US)
Pages (from-to)5-10
Number of pages6
JournalSeminars in Cancer Biology
Volume96
DOIs
StatePublished - Nov 2023

Keywords

  • Hypoxia-inducible factor
  • Immune checkpoint inhibitor
  • Immune evasion
  • Immunotherapy
  • Intratumoral hypoxia

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting intratumoral hypoxia to enhance anti-tumor immunity'. Together they form a unique fingerprint.

Cite this